Skip to main content

Table 1 Patients’ characteristics of our study cohort

From: Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients

Study cohort n=111   n %
Gender Female 48 43
Male 63 57
Age in years Mean 58.9 -
Median 61.2 -
Range 18-85.4 -
MGMT Meth. (mean ≥10%) 56 51
Unmeth. (mean < 10%) 55 49
Toxicity during 1st line therapy CTG °III-IV 4 4
2nd line therapy mTMZ 38 34
TMZ rechallenge 7 6
CCNU+Procarbazine 4 4
BEV 3 3
Re-irradiation 4 4
TTFields 5 5
Re-resection 33 30
Follow up in months Mean 19.4 -
Median 15.4 -
Range 0.3-90 -
Lost to follow up 2 2
PFS in months Mean 12 -
Median 7.8 -
Range 0.3-56 -
OS in months Mean 19.8 -
Median 15.5 -
Range 0.5-90 -
  1. BEV bevacizumab, CCNU lomustin, CTG common toxicity criteria, GTR gross total resection, MGMT O6-methylguanine-DNA-methyltransferase, meth methylated, mTMZ metronomic temozolomide, OS overall survival, PR partial resection, TMZ temozolomide, TTFields tumor treating fields, unmeth  unmethylated